(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33%.
Cervomed's earnings in 2026 is -$28,518,535.On average, 8 Wall Street analysts forecast CRVO's earnings for 2026 to be -$36,293,367, with the lowest CRVO earnings forecast at -$44,033,129, and the highest CRVO earnings forecast at -$22,238,954. On average, 7 Wall Street analysts forecast CRVO's earnings for 2027 to be -$25,963,600, with the lowest CRVO earnings forecast at -$29,058,900, and the highest CRVO earnings forecast at -$15,884,967.
In 2028, CRVO is forecast to generate -$16,974,222 in earnings, with the lowest earnings forecast at -$23,128,512 and the highest earnings forecast at -$13,184,523.